Core Viewpoint - The innovative drug market has seen a significant surge, with Innovent Biologics experiencing over 150% growth year-to-date and a market capitalization exceeding HKD 160 billion [1] Group 1: Market Performance - The Hang Seng Biotechnology Index, which heavily invests in Innovent Biologics and BeiGene, has risen over 80% this year, ranking among the top in overall market indices [1] - The Hang Seng Medical ETF (159892) leads its category with a scale exceeding HKD 6 billion [1] Group 2: Upcoming Developments - The futures for the Hang Seng Biotechnology Index are set to be listed on the Hong Kong Stock Exchange on November 28, providing new risk hedging tools for investors [1] - Innovent Biologics will be included in the Hang Seng Index and the Hang Seng China Enterprises Index, with changes effective after market close on December 5 and effective on December 8 [1] Group 3: Fund Inflows - According to CICC's estimates, the ETF tracking the Hang Seng Index has a fund scale of approximately USD 29.2 billion, while those tracking the China Enterprises and Hang Seng Technology indices have scales of about USD 7.59 billion and USD 32.61 billion, respectively [1] - Innovent Biologics is expected to see an estimated inflow of over USD 364 million due to its inclusion in these indices [1]
恒生指数公司季度检讨结果出炉！信达生物纳入恒生指数、恒生中国企业指数